Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 1, 2018. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital and voting rights data.
- Issued Share Capital (as of September 30, 2018): 5,375,085,545 Ordinary Shares of 25 pence each.
- Treasury Shares: 414,605,950 Ordinary Shares.
- Total Voting Rights: 4,960,479,595.
Material Changes
The filing text does not provide a clear value for material changes versus the prior comparable period. No comparative data from previous periods is included in this specific report.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a statutory notification of share capital figures intended to assist shareholders in calculating notification thresholds under FCA rules.
Investor Verification Checklist
- Verify the total number of voting rights (4,960,479,595) against the latest 20-F annual report to confirm consistency.
- Confirm the number of shares held in Treasury (414,605,950) to ensure accurate calculation of free float.
- Check subsequent filings for any changes in share capital or voting rights following the October 1, 2018 date.